Q-omics provides the consensus-scored C11orf1 profile across patient tissues and cancer cell-line models. C11orf1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, C11orf1 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, C11orf1 protein abundance shows 20,714 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, THCA, and GBM as cancer lineages where C11orf1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C11orf1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C11orf1 survival associations across molecular data types. C11orf1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C11orf1 RNA expression–survival associations across cancer types. High C11orf1 expression shows unfavorable associations in BLCA, but favorable associations in KIRC, UCEC, MESO, UCS and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for C11orf1 RNA expression.
This table summarizes C11orf1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for C11orf1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C11orf1 shows lower tumor expression in THCA, KICH and BRCA and higher tumor expression in COAD, LUAD and CHOL. The THCA box plot shows higher C11orf1 RNA expression in normal versus tumor tissue (log2 FC = −0.642, t-test p < 0.001).
This table shows molecular features associated with C11orf1 in patient tissues and cancer cell lines. In patient samples, C11orf1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, C11orf1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BONE and SKIN.
